PDS Biotechnology (PDSB) AI Stock Analysis

• Market Cap: $49.21M
• Dividend Yield: N/A
• Average Volume (3M): 610.65K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.53
• Revenue Growth: N/A
• EPS Growth: 29.95%
• Country: US
• Employees: 24
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.19
• Shares Outstanding: 54,721,306
• 10 Day Avg. Volume: 619,061
• 30 Day Avg. Volume: 610,652
• PEG Ratio: 0.06
• Price to Book (P/B): 3.13
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.69
• Enterprise Value/Market Cap: 0.84
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -2.74K
• Enterprise Value/Ebitda: -1.35
• 1Y Price Target: $9.00
• Price Target Upside: 889.01% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): -0.67
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: $0.89 ▼(-2.64% Downside)

The score is held down primarily by weak financial performance (no revenue, persistent losses/cash burn, and a diminished equity base), which raises financing risk. Technicals are neutral with only mild signs of improvement, while positive trial/regulatory progress and recent patents/clinical updates provide some offset. Valuation support is limited because losses make the P/E not meaningful and no dividend yield is available.

Positive Factors

Strengthened IP Protection

A newly allowed U.S. patent for PDS0101 and an expanded global patent estate materially strengthens exclusivity around the Versamune platform, creating a durable competitive barrier, improving partner interest, and supporting commercial leverage if clinical/regulatory success is achieved.

Pivotal Clinical Progress

Robust VERSATILE-002 outcomes (notably MOS and durable PFS) and a planned VERSATILE-003 amendment to include PFS as a primary endpoint with FDA engagement reduce regulatory uncertainty, shorten potential approval timelines, and enhance the long-term commercial viability of PDS0101 in HPV16-positive head and neck cancer.

Platform Diversification

Positive NCI-led PDS01ADC signals in mCRPC demonstrate the Versamune/IL-12 approach can be applied beyond the lead asset, diversifying clinical risk, bolstering scientific validation, and increasing partnership or combination therapy opportunities across difficult-to-treat solid tumors.

Negative Factors

Zero Revenue & Persistent Cash Burn

The company generates no product revenue and has sustained large negative operating and free cash flow, meaning R&D and operations are funded externally. This ongoing cash burn creates structural financing dependence and raises the risk of dilution or program delays absent successful partnerships or approvals.

Eroding Equity Base & Leverage

Equity has declined materially over several years while meaningful debt remains, increasing leverage and reducing balance sheet flexibility. This structural weakening limits the company's ability to absorb trial setbacks, negotiate favorable partnerships, or fund late-stage development without dilutive financing.

Diminishing Cash Runway / Funding Risk

Cash fell materially during the year and the company has relied on financing (an $11.1M securities purchase agreement) to support trials. This creates structural execution risk: ongoing development depends on additional funding that could dilute shareholders or delay programs if capital markets or partner deals are constrained.

PDS Biotechnology Business Overview & Revenue Model

Company Description

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.

How the Company Makes Money

PDS Biotechnology primarily generates revenue through strategic partnerships, collaborations, and licensing agreements with larger pharmaceutical companies and research institutions. These partnerships often involve milestone payments and royalties based on the development and commercialization of their Versamune®-based products. Additionally, the company may receive funding from government grants and research subsidies aimed at supporting advancements in cancer immunotherapy and vaccine development. As a clinical-stage company, PDS Biotech is still in the process of moving its products through clinical trials, with the potential for future revenue from product sales upon successful market approval.

PDS Biotechnology Financial Statement Overview

Summary

Fundamentals are weak: zero revenue, ongoing large operating losses (TTM EBIT about -$32.2M) and cash burn (TTM operating cash flow/free cash flow about -$32.3M). While losses narrowed modestly versus prior years, equity has fallen sharply to ~$9.5M TTM with still-meaningful debt (~$18.0M), elevating financing risk.

Income Statement

Results remain highly challenged: the company reports zero revenue across all provided periods (annual and TTM (Trailing-Twelve-Months)), while operating losses are persistent (TTM EBIT about -$32.2M; net loss about -$34.9M). Losses have improved versus 2022–2024 (net loss narrowed from roughly -$40.9M in 2022 and -$42.9M in 2023 to -$37.6M in 2024 and -$34.9M TTM), but profitability is still deeply negative, indicating continued dependence on external funding.

Balance Sheet

Balance sheet strength has weakened materially over time as equity has declined from about $63.2M (2021) to $19.0M (2024) and $9.5M TTM (Trailing-Twelve-Months), consistent with ongoing losses and dilution/financing needs. Total debt is meaningful at ~$18.0M TTM, and leverage rose sharply versus earlier years (low debt in 2020–2021). A positive is that total debt has come down from ~$23.9M (2023) and ~$21.8M (2024) to ~$18.0M TTM, but the reduced equity base increases financial risk and limits flexibility.

Cash Flow

Cash generation remains weak with consistently negative operating cash flow and free cash flow (TTM operating cash flow about -$32.3M; free cash flow about -$32.3M). Cash burn improved versus 2024 (operating cash flow ~-$35.0M) but remains large, and TTM free cash flow growth is strongly negative, signaling accelerating cash outflows versus the prior comparable period. Free cash flow roughly tracks net loss, implying the losses are largely translating into cash burn rather than being offset by non-cash items.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-15.13K	-59.79K	-57.33K	0.00	0.00	0.00
EBITDA	-30.71M	-33.75M	-40.09M	-40.74M	-21.43M	-14.89M
Net Income	-34.88M	-37.61M	-42.94M	-40.85M	-16.92M	-14.85M
Balance Sheet
Total Assets	34.71M	45.36M	59.39M	77.01M	67.20M	30.89M
Cash, Cash Equivalents and Short-Term Investments	26.20M	41.69M	56.56M	73.82M	65.24M	28.84M
Total Debt	17.97M	21.83M	23.85M	23.47M	490.35K	610.26K
Total Liabilities	25.25M	26.35M	33.26M	33.01M	3.99M	3.76M
Stockholders Equity	9.45M	19.00M	26.13M	44.00M	63.21M	27.13M
Cash Flow
Free Cash Flow	-32.28M	-35.06M	-33.64M	-25.71M	-12.49M	-13.15M
Operating Cash Flow	-32.28M	-35.03M	-33.64M	-25.71M	-12.49M	-13.15M
Investing Cash Flow	0.00	-29.00K	0.00	0.00	0.00	0.00
Financing Cash Flow	8.73M	20.19M	16.38M	34.29M	48.89M	29.83M

PDS Biotechnology Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.91
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PDSB, the sentiment is Negative. The current price of 0.91 is below the 20-day moving average (MA) of 0.92, above the 50-day MA of 0.88, and below the 200-day MA of 1.13, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 48.58 is Neutral, neither overbought nor oversold. The STOCH value of 23.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PDSB.

PDS Biotechnology Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LTRN	50 Neutral	$37.02M	-1.81	-104.58%	―	―	1.18%
SNTI	48 Neutral	$27.87M	-0.31	-394.62%	―	―	78.60%
PDSB	47 Neutral	$49.21M	-1.11	-221.81%	―	―	29.95%
TPST	44 Neutral	$14.49M	-0.28	-405.03%	―	―	49.43%
CALC	44 Neutral	$73.78M	-0.78	-526.36%	―	―	-2.46%

PDS Biotechnology Corporate Events

PDS Biotechnology Highlights Promising Phase 2 Prostate Cancer Data

On January 28, 2026, PDS Biotechnology announced that the National Cancer Institute presented preliminary Phase 2 results for its investigational IL-12 tumor-targeted immunocytokine PDS01ADC at an American Association for Cancer Research conference on prostate cancer held in Boston on January 20-22, 2026. The NCI-led study evaluated PDS01ADC in combination with docetaxel in patients with metastatic castration-resistant prostate cancer who had largely exhausted second-line androgen-targeted therapies, reporting a median progression-free survival of 9.6 months and a median PSA decline of 40%, with six of 16 patients achieving PSA reductions greater than 50%. The data, highlighting the agent’s tumor-targeted IL-12 mechanism via binding to necrotic DNA, bolster PDS Biotech’s immuno-oncology pipeline by suggesting the potential to enhance existing therapies in difficult-to-treat solid tumors, an important signal for the company’s strategic positioning in late-stage cancer immunotherapy development.

The most recent analyst rating on (PDSB) stock is a Hold with a $0.93 price target. To see the full list of analyst forecasts on PDS Biotechnology stock, see the PDSB Stock Forecast page.

PDS Biotechnology Secures Key Patent Strengthening PDS0101 Protection

On January 22, 2026, PDS Biotechnology announced that the U.S. Patent Office issued a Notice of Allowance for a new U.S. patent covering technology underlying its lead asset PDS0101, a cancer immunotherapy based on the company’s Versamune platform. The patent, titled “Methods and Compositions Comprising Cationic Lipids for Stimulating Type I Interferon Genes,” will provide broad composition and method-of-use claims and strengthens PDS Biotech’s intellectual property estate, which already includes patents across major markets including the U.S., Europe, Japan, China, Australia, Canada, Israel, Mexico, and Hong Kong. Together with anticipated U.S. biologics exclusivity, the patent is expected to secure roughly 20 years of market protection for PDS0101, which is being tested in the Phase 3 VERSATILE-003 trial in HPV16-positive head and neck cancers. The company has also submitted an FDA protocol amendment for this pivotal trial to make progression-free survival the earlier-evaluable primary endpoint for accelerated approval, while median overall survival remains the primary endpoint for full approval, potentially sharpening PDS Biotech’s path to market and reinforcing its competitive positioning in oncology immunotherapies.

The most recent analyst rating on (PDSB) stock is a Hold with a $0.93 price target. To see the full list of analyst forecasts on PDS Biotechnology stock, see the PDSB Stock Forecast page.

PDS Biotechnology Updates Phase 3 Trial Design for PDS0101

On January 9, 2026, PDS Biotechnology announced it had submitted a protocol amendment to the U.S. Food and Drug Administration for its Phase 3 VERSATILE-003 trial of PDS0101 in HPV16-positive recurrent and/or metastatic head and neck cancer, following a constructive Type C meeting with the agency in December 2025. The amendment designates progression-free survival as the primary endpoint that can be evaluated earlier, potentially shortening trial duration and supporting an accelerated approval pathway, while median overall survival and safety remain key requirements for full approval, a move underpinned by positive final results from the earlier VERSATILE-002 study showing promising survival and durable progression-free outcomes.

The most recent analyst rating on (PDSB) stock is a Hold with a $0.80 price target. To see the full list of analyst forecasts on PDS Biotechnology stock, see the PDSB Stock Forecast page.

PDS Biotechnology Secures New Patent for PDS0101

On December 9, 2025, PDS Biotechnology Corporation announced that the Japan Patent Office issued a new patent for PDS0101, expanding its intellectual property estate. This development strengthens the company’s global IP portfolio, providing patent and market protections for PDS0101 into the 2040s, and supports the company’s growth as it advances its pipeline worldwide.

The most recent analyst rating on (PDSB) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on PDS Biotechnology stock, see the PDSB Stock Forecast page.

PDS Biotechnology Gains FDA Meeting for PDS0101 Approval

On December 2, 2025, PDS Biotechnology announced that the FDA accepted its request for a Type C Meeting to discuss an accelerated approval pathway for its PDS0101 treatment in HPV16-positive head and neck cancer. This meeting, scheduled for December 2025, aims to explore amendments to the Phase 3 VERSATILE-003 trial, potentially expediting the treatment’s availability to patients based on positive results from the VERSATILE-002 trial.

The most recent analyst rating on (PDSB) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on PDS Biotechnology stock, see the PDSB Stock Forecast page.

PDS Biotechnology Announces $11.1M Securities Purchase Agreement

On November 11, 2025, PDS Biotechnology Corporation announced a securities purchase agreement to raise up to $11.1 million through the sale of common stock and warrants, with the offering expected to close on November 12, 2025. The proceeds will support the company’s ongoing VERSATILE-003 Phase 3 clinical trial and other research and development activities, potentially impacting its operational capabilities and market position.

The most recent analyst rating on (PDSB) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on PDS Biotechnology stock, see the PDSB Stock Forecast page.

PDS Biotechnology Announces Positive Data at Cancer Meeting

On November 10, 2025, PDS Biotechnology Corporation announced positive clinical and translational data at the 2025 Society for Immunotherapy of Cancer Annual Meeting. The data showcased immune-driven mechanisms and biomarkers explaining the strong clinical activity of their investigational therapies PDS0101 and PDS01ADC. These findings, part of a collaboration with the National Cancer Institute, highlight the therapies’ ability to activate immune responses, including natural killer and memory T cells, which are crucial for long-term tumor control. The results support the company’s regulatory strategy and ongoing clinical trials, reinforcing the scientific foundation of their immunotherapy platforms.

The most recent analyst rating on (PDSB) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on PDS Biotechnology stock, see the PDSB Stock Forecast page.

PDS Biotechnology Seeks FDA Meeting for PDS0101 Approval

On October 29, 2025, PDS Biotechnology announced its request for a meeting with the FDA to explore an expedited approval pathway for its immunotherapy drug PDS0101, targeting HPV16-positive head and neck cancer. This decision follows promising results from the VERSATILE-002 trial, showing significant median progression-free and overall survival rates, and aims to amend the ongoing VERSATILE-003 trial to include progression-free survival as an earlier primary endpoint. This strategic move could potentially accelerate the drug’s availability to patients, positioning PDS Biotechnology as a leader in providing innovative cancer treatments.

The most recent analyst rating on (PDSB) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on PDS Biotechnology stock, see the PDSB Stock Forecast page.